PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24200972-5	2014	Lapatinib-resistant cells have an increased Src kinase activity and persistent levels of activation of ERK1/2 and AKT compared with parental cells.	Lapatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	114-117	
24200972-6	2014	Treatment with the Src inhibitor saracatinib in combination with lapatinib reduces AKT and ERK1/2 phosphorylation and restores the sensitivity of resistant cells to lapatinib.	Lapatinib	65-74	AKT serine/threonine kinase 1	Homo sapiens	83-86